Next 10 |
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in foll...
2024-04-17 17:01:03 ET Gainers: Vanda Pharmaceuticals ( VNDA ) +7% . Sutro Biopharma ( STRO ) +5% . CureVac ( CVAC ) +5% . CorMedix ( CRMD ) +4% . Bank OZK ( OZK ) +4% . Losers: Omega Therapeutics ( OM...
2024-04-05 18:31:56 ET Summary Ipsen S.A. is a pharmaceutical company focused on oncology, rare disease, and neuroscience, with a portfolio of commercial drug products. The company generated $3.4bn in revenues in 2023, with a core consolidated net profit of $830m. Ipsen typica...
2024-04-03 17:00:02 ET Jay Olson from Oppenheimer issued a price target of $10.00 for STRO on 2024-04-03 14:01:00. The adjusted price target was set to $10.00. At the time of the announcement, STRO was trading at $5.09. The overall price target consensus is at $14.50 wit...
2024-04-03 08:00:08 ET Edward Tenthoff from Piper Sandler issued a price target of $11.00 for STRO on 2024-04-03 06:48:00. The adjusted price target was set to $11.00. At the time of the announcement, STRO was trading at $5.09. The overall price target consensus is at $1...
2024-04-02 06:36:56 ET More on Sutro Biopharma Ipsen secures exclusive global rights of Sutro Biopharma's STRO-003 ADC Seeking Alpha’s Quant Rating on Sutro Biopharma Historical earnings data for Sutro Biopharma Financial information for Sutro Biopharm...
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 14,4...
2024-04-02 04:03:00 ET Ipsen ( OTCPK:IPSEY ) has secured exclusive global rights for the development and commercialization of STRO-003, an antibody-drug conjugate, from Sutro Biopharma ( NASDAQ: STRO ), completing the final stages of pre-clinical development, the compa...
2024-03-27 08:24:20 ET More on premarket gainers & stock Veritone: Not An AI Stock To Bank On Veritone, Inc. (VERI) Q4 2023 Earnings Call Transcript Mesoblast Limited (MESO) Q2 2024 Earnings Call Transcript Mesoblast gains as FDA backs regulatory plans fo...
2024-03-26 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for STRO on March 26, 2024 06:07AM ET. The previous analyst recommendation was Buy. STRO was trading at $3.27 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
News, Short Squeeze, Breakout and More Instantly...
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in foll...
2024-04-03 17:00:02 ET Jay Olson from Oppenheimer issued a price target of $10.00 for STRO on 2024-04-03 14:01:00. The adjusted price target was set to $10.00. At the time of the announcement, STRO was trading at $5.09. The overall price target consensus is at $14.50 wit...
2024-04-03 08:00:08 ET Edward Tenthoff from Piper Sandler issued a price target of $11.00 for STRO on 2024-04-03 06:48:00. The adjusted price target was set to $11.00. At the time of the announcement, STRO was trading at $5.09. The overall price target consensus is at $1...